118.74
-1.205(-1.00%)
Currency In USD
| Previous Close | 119.94 |
| Open | 119.86 |
| Day High | 120.79 |
| Day Low | 117.5 |
| 52-Week High | 139.13 |
| 52-Week Low | 75.56 |
| Volume | 52,262 |
| Average Volume | 586,890 |
| Market Cap | 5.93B |
| PE | -23.47 |
| EPS | -5.06 |
| Moving Average 50 Days | 114.91 |
| Moving Average 200 Days | 109.86 |
| Change | -1.21 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) since IPO date, it would be worth $13,585.24 as of October 07, 2025 at a share price of $118.735. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $1,628.29 as of October 07, 2025 at a share price of $118.735.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
GlobeNewswire Inc.
3 hours ago
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apneaNEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM)
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
GlobeNewswire Inc.
Jul 21, 2025 11:30 AM GMT
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast it